Latest Inflammatory Diseases News

Page 4 of 5
Noxopharm’s Sofra™ technology shows promising results in collaboration with US biotech Tezcat Biosciences, advancing targeted drug delivery for cancer and inflammatory diseases.
Ada Torres
Ada Torres
5 Aug 2025
Patrys Limited has completed a modest capital raise and restructured its leadership as it advances its deoxymab antibody program, with a larger entitlement offer announced to fund clinical development and business growth.
Ada Torres
Ada Torres
29 July 2025
Syntara Limited has initiated dosing in its Phase 1a/b trial for SNT-9465, a topical drug targeting hypertrophic scars, aiming to offer a non-invasive alternative to current treatments. Results expected in early 2026 could pave the way for global development and FDA approval.
Ada Torres
Ada Torres
29 July 2025
Noxopharm Limited has successfully completed the first low-dose cohort in its HERACLES clinical trial for SOF-SKN™, clearing the way for higher dose testing in autoimmune disease treatment.
Ada Torres
Ada Torres
28 July 2025
Patrys Limited has announced a fully underwritten entitlement offer to raise approximately $1.77 million, aimed at funding ongoing research and development of its PAT-DX3 therapy and supporting working capital. The offer includes secondary options and shares, subject to shareholder approval, and will significantly expand the company's capital base.
Ada Torres
Ada Torres
23 July 2025
Syntara Limited reports encouraging interim Phase 2 data for its drug SNT-5505 combined with ruxolitinib, demonstrating significant symptom relief and spleen volume reduction in myelofibrosis patients. The company plans to engage the FDA soon to discuss pivotal trial design.
Ada Torres
Ada Torres
13 June 2025
Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.
Ada Torres
Ada Torres
10 June 2025
Dimerix has activated the first clinical trial site in Japan for its pivotal Phase 3 ACTION3 study targeting FSGS, triggering a significant milestone payment from its Japanese partner FUSO Pharmaceutical.
Ada Torres
Ada Torres
30 May 2025
Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.
Ada Torres
Ada Torres
29 May 2025
Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a sixth Medicare Administrative Contractor, covering over 85% of US Medicare payment regions. This milestone advances the company’s commercialisation efforts in the US healthcare market.
Ada Torres
Ada Torres
27 May 2025
Dimerix Limited’s ACTION3 Phase 3 trial for DMX-200 in treating FSGS kidney disease has passed its sixth independent safety review with no concerns, reinforcing the drug’s promising safety profile.
Ada Torres
Ada Torres
22 May 2025
Noxopharm Limited has raised nearly $2.5 million by selling its entire stake in Nyrada Inc, providing non-dilutive capital to advance its HERACLES clinical trial and expand its research pipeline.
Ada Torres
Ada Torres
20 May 2025

Browse the archive

Full archive